Treatment rationale and design of a phase II study of narrow-band ultraviolet B phototherapy for cutaneous steroid-refractory acute graft-vs-host disease following allogenic stem-cell transplantation

• Published in: Medicine Vol. 98; no. 28; p. e16372
• Main Authors: Asai, Jun, Yamaguchi, Junko, Tsukamoto, Taku, Chinen, Yoshiaki, Shimura, Yuji, Kobayashi, Tsutomu, Katoh, Norito, Kuroda, Junya
• Format: Journal Article
• Language: English
• Published: United States Ovid Technologies (Wolters Kluwer Health) 01.07.2019; the Author(s). Published by Wolters Kluwer Health, Inc; Wolters Kluwer Health
• Subjects: Acute Disease; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents - therapeutic use; Clinical Trials, Phase II as Topic; Drug Resistance; Graft vs Host Disease; Graft vs Host Disease - therapy; Humans; Middle Aged; Research Article; Retreatment; Skin Diseases; Skin Diseases - etiology; Skin Diseases - therapy; Stem Cell Transplantation; Steroids; Steroids - therapeutic use; Study Protocol Clinical Trial; Transplantation, Homologous; Ultraviolet Therapy; Ultraviolet Therapy - adverse effects; Ultraviolet Therapy - methods; Young Adult
• ISSN: 0025-7974; 1536-5964; 1536-5964
• DOI: 10.1097/md.0000000000016372

Acute graft-vs-host disease (aGVHD) is a common complication of allogenic hematopoietic stem-cell transplantation (allo-HSCT) and skin is the most common and often the 1st site at which aGVHD develops. Cutaneous aGVHD is usually treated with oral and/or topical corticosteroids as the 1st-line treatment; however, steroid-refractory aGVHD not only impairs patients' quality of life but also causes significant morbidity and mortality after allo-HSCT. Narrow-band ultraviolet B (NB-UVB) phototherapy has been utilized for a wide range of immunologic inflammatory skin diseases, but there is limited information on the efficacy, safety, and biomarkers for response prediction of NB-UVB for cutaneous aGVHD. The purpose of this study is to investigate the efficacy and safety of NB-UVB phototherapy for steroid-refractory cutaneous aGVHD. A total of 40 subjects aged from 16 to 70 years with steroid-refractory cutaneous aGVHD after allo-HSCT will be included in the trial. Patients with worse than stage 2 intestine/liver aGVHD will be excluded. Eligible patients will undergo NB-UVB phototherapy until resolution or further worsening of rash or occurrence of an unmanageable adverse event. The primary endpoint is the overall response rate. The secondary outcomes include rates for complete response, partial response, stable disease, progressive disease, duration of response, sparing effect on calcineurin inhibitors and/or corticosteroids, safety, and predictive biomarkers for treatment response. The protocol has been approved by the institutional Clinical Research Review Board of Kyoto Prefectural University of Medicine. Written informed consent will be obtained from all patients before registration, in accordance with the Declaration of Helsinki. Results of the study will be disseminated via publications in peer-reviewed journals. Trial registration numbers UMIN000032426 and jRCTs052180005.